Shots:
- The US FDA has granted accelerated approval to Emrelis (telisotuzumab vedotin-tllv) for treatment-experienced pts with locally advanced or metastatic, c-Met overexpressing, non-squamous NSCLC
- Approval was backed by an ongoing P-II (LUMINOSITY) study assessing Emrelis as 2L/3L treatment of c-Met overexpressing NSCLC; showing an ORR of 35% & mDoR of 7.2mos. in pts (n=84) with high c-Met protein overexpression
- Emrelis is also being evaluated as a monotx. in P-III (TeliMET NSCLC-01) confirmatory trial for previously treated c-Met overexpressing NSCLC, with global enrollment underway
Ref: AbbVie | Image: AbbVie| Press Release
Related News:- AbbVie Partners with ADARx Pharmaceuticals to Develop siRNA Therapies Across Multiple Disease Areas
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
